April's SLAS Discovery now available

March 23, 2020

Oak Brook, IL - April's edition of SLAS Discovery features the cover article, "Maximizing the Value of Cancer Drug Screening in Multicellular Tumor Spheroid Cultures: A Case Study in Five Head and Neck Squamous Cell Carcinoma Cell Lines." Stanton J. Kochanek, Ph.D., David A. Close, Ph.D., Daniel P. Camarco, Ph.D., and Paul A. Johnston, Ph.D., (University of Pittsburgh, PA, USA) disseminate their recent study that shows how incorporating morphology and dead cell readouts into cancer drug screening helps improve the drug selection rate.

Consistent with solid tumors, multicellular tumor spheroids (MCTS) develop gradients of nutrient distribution and oxygen concentration resulting in diverse microenvironments with differential proliferation and drug distribution zones. Kochanek, Close, Camarco and Johnston produced head and neck squamous cell carcinoma (HNSCC) MCTSs and used viability reagents and imaging methods to measure the effects of anti-cancer drug exposure. This step revealed that cell viability reagents under-estimate the impact of drug exposure in HNSCC MCTS cultures, but that incorporating morphology and dead cell readouts increased the number of drugs judged to have substantially impacted MCTS cultures.

A multi-parameter drug impact score provided a way to stratify MCTS drug responses and maximize the value of these more physiologically relevant tumor cultures.

Currently, cancer drug approval rates are less than 5%, while the overall probability of success in oncology clinical trials is 3.4%. Kochanek, Close, Camarco and Johnston continue to build on their current research to help improve these cancer drug discovery and development success rates through the use of more physiologically relevant and complex 3D models featured in this study.

The group's lead researcher, Paul A. Johnston, has 30 years of drug discovery experience in the pharmaceutical, biotechnology and academic sectors. As an innovator of cell-based lead generation, he pioneered the implementation of high-content imaging technology for drug discovery, and in 2005 helped create the University of Pittsburgh Molecular Library Screening Center (Pittsburgh, PA, USA). In 2011, Johnston established his own chemical biology laboratories within the University's Department of Pharmaceutical Sciences of the School of Pharmacy in order to conduct research on the application of novel drug discovery strategies to find new and effective drugs or drug combinations for prostate cancer, melanoma, head and neck cancer and hepatocellular carcinoma.
Access to "Maximizing the Value of Cancer Drug Screening in Multicellular Tumor Spheroid Cultures: A Case Study in Five Head and Neck Squamous Cell Carcinoma Cell Lines" is available at https://journals.sagepub.com/toc/jbxb/25/4 until April 20.

For more information about SLAS and its journals, visit http://www.slas.org/journals.

SLAS (Society for Laboratory Automation and Screening) is an international community of 16,000 professionals and students dedicated to life sciences discovery and technology.

The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.

SLAS Discovery: Advancing the Science of Drug Discovery, 2018 Impact Factor 2.192. Editor-in-Chief Robert M. Campbell, Ph.D., Eli Lilly and Company, Indianapolis, IN (USA).

SLAS Technology: Translating Life Sciences Innovation, 2018 Impact Factor 2.048. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore).

SLAS (Society for Laboratory Automation and Screening)

Related Cancer Drug Articles from Brightsurf:

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

New opportunity for cancer drug development
After years of research on cell surface receptors called Frizzleds, researchers at Karolinska Institutet in Sweden provide the proof-of-principle that these receptors are druggable by small molecules.

Choosing the right drug to fight cancer
Biochemists at Université de Montreal discover a new mechanism to better predict whether an anti-cancer therapy will work.

Yale study identifies how cancer drug inhibits DNA repair in cancer cells
According to researchers at Yale Cancer Center, a cancer drug thought to be of limited use possesses a superpower of sorts: It is able to stop certain cancer cells from repairing their DNA in order to survive.

Testing cells for cancer drug resistance
Biophysicists at Ruhr-Universität Bochum (RUB) have demonstrated that Raman microscopy can be used to detect the resistance of tumour cells to cancer drugs.

ALS drug may help treat prostate cancer
Researchers have discovered a new use for an old drug as a potential treatment for prostate cancer.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.

New lab study reveals how breast cancer drug can accelerate cancer cell growth
The breast cancer drug lapatinib which is designed to shrink tumors can sometimes cause them to grow in the lab, according to a new study.

Read More: Cancer Drug News and Cancer Drug Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.